Impacts of Hepatitis B and Hepatitis C Co-infection with Tuberculosis, a Prospective Cohort Study

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2020 Jul 25

PMID 32703225

Citations 5

Authors

Berhanu Elfu Feleke

Teferi Elfu Feleke

Wondimu Gebrekiros Adane

Abel Girma

Affiliations

Soon will be listed here.

Abstract

Background: This study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis.

Methods: Prospective cohort study design was implemented. The data were collected from September 2016 - May 2019. Systematic random sampling was used to select the study participants. Baseline data were collected before the patient starts DOTS, the sign of liver toxicity was assessed every week. Tuberculosis treatment outcomes and WHO clinical stage was recorded at the end of 6th months. Descriptive statistics were used to estimate the prevalence of hepatitis B, hepatitis C viral infections and their effect on tuberculosis treatment outcomes. Binary logistic regression was used to identify the determinants of hepatitis B and C infections. The Kaplan Meier survival curve was used to estimate the survival of tuberculosis patient and Cox regression was used to identify the predictors of drug-induced hepatitis.

Results: A total of 3537 tuberculosis patients were followed. The prevalence of hepatitis B and C viral infection among tuberculosis patients were 15.1 and 17.3% respectively. Hepatitis B viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. Hepatitis C viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. The incidence density for liver toxicity among tuberculosis patients was 843/15707 person-months and liver toxicity was determined by HIV, Hepatitis B, Hepatitis C, the severity of tuberculosis and chronic illnesses.

Conclusion: Decision-makers should consider incorporating screening for hepatitis B and C viral infection during tuberculosis treatment.

Citing Articles

Risk factors for viral hepatitis in pulmonary tuberculosis patients undergoing treatment: A systematic review and meta-analysis.

Ilham A, Andini S, Afladhia H, Rakasiwi M, Burhan E Narra J. 2025; 4(3):e1242.

PMID: 39816129 PMC: 11731815. DOI: 10.52225/narra.v4i3.1242.

Risk of Hepatitis C Virus Infection in Tuberculosis Patients: A Systematic Review and Meta-Analysis.

Amoori N, Cheraghian B, Amini P, Alavi S Iran J Public Health. 2024; 53(11):2451-2461.

PMID: 39619916 PMC: 11607145. DOI: 10.18502/ijph.v53i11.16947.

Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort.

Jansen van Vuuren J, Crocker-Buque T, Berry C, Viatushka D, Usmanova R, Nyangwa B PLOS Glob Public Health. 2024; 4(9):e0003057.

PMID: 39316626 PMC: 11421810. DOI: 10.1371/journal.pgph.0003057.

Hepatitis B and C virus infections and associated factors among HIV-positive and HIV-negative tuberculosis patients in public health facilities, Northeast Ethiopia: A comparative cross-sectional study.

Gedefie A, Seid A, Fenta G, Tilahun M, Shibabaw A, Ali A SAGE Open Med. 2023; 11:20503121231166642.

PMID: 37123386 PMC: 10134168. DOI: 10.1177/20503121231166642.

Prevalence and factors associated with hepatitis B and C virus infections among female Sex workers in Ethiopia: Results of the national biobehavioral Survey, 2020.

Bedassa B, Ebo G, Yimam J, Tura J, Wariso F, Lulseged S PLoS One. 2022; 17(12):e0269510.

PMID: 36584042 PMC: 9803120. DOI: 10.1371/journal.pone.0269510.

References

Chen Y, Su Y, Li C, Wu C, Lee M . A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2014; 87(5):1030-8. DOI: 10.1038/ki.2014.363. View

Uehara S, Emori C, Perez R, Mendes-Correa M, Ferreira A, Feldner A . High incidence of tuberculosis in patients treated for hepatitis C chronic infection. Braz J Infect Dis. 2016; 20(2):205-9. PMC: 9427596. DOI: 10.1016/j.bjid.2015.12.003. View

Reis N, Lopes C, Teles S, Matos M, Carneiro M, Marinho T . Hepatitis C virus infection in patients with tuberculosis in Central Brazil. Int J Tuberc Lung Dis. 2012; 15(10):1397-402. DOI: 10.5588/ijtld.10.0636. View

Vom Steeg L, Klein S . SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog. 2016; 12(2):e1005374. PMC: 4759457. DOI: 10.1371/journal.ppat.1005374. View

Wieland S, Thimme R, Purcell R, Chisari F . Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004; 101(17):6669-74. PMC: 404103. DOI: 10.1073/pnas.0401771101. View

Franco E, Bagnato B, Marino M, Meleleo C, Serino L, Zaratti L . Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4(3):74-80. PMC: 3321493. DOI: 10.4254/wjh.v4.i3.74. View

Binka M, Butt Z, Wong S, Chong M, Buxton J, Chapinal N . Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada. World J Gastroenterol. 2018; 24(11):1216-1227. PMC: 5859224. DOI: 10.3748/wjg.v24.i11.1216. View

Wang S, Chen P, Yeh S . Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. J Gastroenterol Hepatol. 2015; 30(8):1237-45. DOI: 10.1111/jgh.12934. View

Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y . Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014; 28:95-100. DOI: 10.1016/j.ijid.2014.06.020. View

10.

Hughes E, Bassi S, Gilbody S, Bland M, Martin F . Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2015; 3(1):40-48. PMC: 4703902. DOI: 10.1016/S2215-0366(15)00357-0. View

11.

Pukenyte E, Lescure F, Rey D, Rabaud C, Hoen B, Chavanet P . Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007; 11(1):78-84. View

12.

Abera B, Adem Y, Yimer M, Mulu W, Zenebe Y, Mekonnen Z . Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia. Virol J. 2017; 14(1):21. PMC: 5294870. DOI: 10.1186/s12985-017-0696-6. View

13.

Bao Y, Ma X, Rasmussen T, Zhong X . Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury. Curr Pharmacol Rep. 2018; 4(3):171-181. PMC: 6241288. DOI: 10.1007/s40495-018-0131-8. View

14.

Chen L, Bao D, Gu L, Gu Y, Zhou L, Gao Z . Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018; 18(1):295. PMC: 6029116. DOI: 10.1186/s12879-018-3192-8. View

15.

Araujo-Mariz C, Lopes E, Ximenes R, Lacerda H, Miranda-Filho D, Montarroyos U . Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis. J Med Virol. 2015; 88(6):996-1002. DOI: 10.1002/jmv.24432. View

16.

Large M, Kittlesen D, Hahn Y . Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 1999; 162(2):931-8. View

17.

Arnold K, Burgener A, Birse K, Romas L, Dunphy L, Shahabi K . Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2015; 9(1):194-205. DOI: 10.1038/mi.2015.51. View

18.

Kebede A, Alebachew Z, Tsegaye F, Lemma E, Abebe A, Agonafir M . The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011. Int J Tuberc Lung Dis. 2014; 18(6):635-9. DOI: 10.5588/ijtld.13.0417. View

19.

Iglecias L, Puga M, Pompilio M, Teles S, Croda J, Lima L . Epidemiological study of hepatitis B virus among prisoners with active tuberculosis in Central Brazil. Int J Tuberc Lung Dis. 2016; 20(11):1509-1515. DOI: 10.5588/ijtld.15.0743. View

20.

Krajden M, Cook D, Wong S, Yu A, Butt Z, Rossi C . What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada. Int J Drug Policy. 2019; 72:114-122. DOI: 10.1016/j.drugpo.2019.06.003. View